FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1618705644> ?p ?o ?g. }

• W1618705644 endingPage "2687" @default.
• W1618705644 startingPage "2687" @default.
• W1618705644 abstract "A JAK2(V617F) mutation is found in approximately 55% of patients with essential thrombocythemia (ET), and represents a key World Health Organization diagnostic criterion. This hypothesis-generating study (NCT01352585) explored the impact of JAK2(V617F) mutation status on treatment response to anagrelide in patients with ET who were intolerant/refractory to their current cytoreductive therapy. The primary objective was to compare the proportion of JAK2-positive versus JAK2-negative patients who achieved at least a partial platelet response (≤600×10(9)/L) after anagrelide therapy. Of the 47 patients enrolled, 46 were included in the full analysis set (JAK2-positive, n=22; JAK2-negative, n=24). At 12 months, 35 patients (n=14 and n=21, respectively) had a suitable platelet sample; of these, 74.3% (n=26) achieved at least a partial response. The response rate was higher in JAK2-positive (85.7%, n=12) versus JAK2-negative patients (66.7%, n=14) (odds ratio [OR] 3.00; 95% confidence interval [CI] 0.44, 33.97). By using the last observation carried forward approach in the sensitivity analysis, which considered the imbalance in patients with suitable samples between groups, the overall response rate was 71.7% (n=33/46), with 77.3% (n=17/22) of JAK2-positive and 66.7% (n=16/24) of JAK2-negative patients achieving at least a partial response (OR 1.70; 95% CI 0.39, 8.02). There was no significant change in median allele burden over 12 months in the 12 patients who achieved a response. In conclusion, the overall platelet response rate was high in both JAK2-positive and JAK2-negative patients; however, a larger study would be required to confirm the differences observed according to JAK2(V617F) mutation status." @default.
• W1618705644 created "2016-06-24" @default.
• W1618705644 creator A5002133396 @default.
• W1618705644 creator A5002512182 @default.
• W1618705644 creator A5006810419 @default.
• W1618705644 creator A5019800434 @default.
• W1618705644 creator A5041745367 @default.
• W1618705644 creator A5046772202 @default.
• W1618705644 creator A5054304877 @default.
• W1618705644 creator A5057084037 @default.
• W1618705644 creator A5057593886 @default.
• W1618705644 creator A5060121000 @default.
• W1618705644 creator A5069419008 @default.
• W1618705644 creator A5069887195 @default.
• W1618705644 creator A5071466957 @default.
• W1618705644 creator A5078922292 @default.
• W1618705644 creator A5083693070 @default.
• W1618705644 creator A5091664535 @default.
• W1618705644 date "2015-05-01" @default.
• W1618705644 modified "2023-09-25" @default.
• W1618705644 title "Impact of JAK2(V617F) mutation status on treatment response to anagrelide in essential thrombocythemia: an observational, hypothesis-generating study" @default.
• W1618705644 cites W1970553871 @default.
• W1618705644 cites W1980568348 @default.
• W1618705644 cites W1983262956 @default.
• W1618705644 cites W1983412285 @default.
• W1618705644 cites W1990387953 @default.
• W1618705644 cites W1997087590 @default.
• W1618705644 cites W2013609774 @default.
• W1618705644 cites W2022750639 @default.
• W1618705644 cites W2024703435 @default.
• W1618705644 cites W2051259791 @default.
• W1618705644 cites W2057360098 @default.
• W1618705644 cites W2069651950 @default.
• W1618705644 cites W2075970562 @default.
• W1618705644 cites W2078182058 @default.
• W1618705644 cites W2087934326 @default.
• W1618705644 cites W2107139993 @default.
• W1618705644 cites W2107398329 @default.
• W1618705644 cites W2121497524 @default.
• W1618705644 cites W2126665281 @default.
• W1618705644 cites W2133633030 @default.
• W1618705644 cites W2138709799 @default.
• W1618705644 cites W2144664431 @default.
• W1618705644 cites W2146505525 @default.
• W1618705644 cites W2157114147 @default.
• W1618705644 cites W2157694607 @default.
• W1618705644 cites W2168062293 @default.
• W1618705644 cites W2169405856 @default.
• W1618705644 cites W3190659723 @default.
• W1618705644 doi "https://doi.org/10.2147/dddt.s79576" @default.
• W1618705644 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4441358" @default.
• W1618705644 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26028965" @default.
• W1618705644 hasPublicationYear "2015" @default.
• W1618705644 type Work @default.
• W1618705644 sameAs 1618705644 @default.
• W1618705644 citedByCount "2" @default.
• W1618705644 countsByYear W16187056442016 @default.
• W1618705644 countsByYear W16187056442022 @default.
• W1618705644 crossrefType "journal-article" @default.
• W1618705644 hasAuthorship W1618705644A5002133396 @default.
• W1618705644 hasAuthorship W1618705644A5002512182 @default.
• W1618705644 hasAuthorship W1618705644A5006810419 @default.
• W1618705644 hasAuthorship W1618705644A5019800434 @default.
• W1618705644 hasAuthorship W1618705644A5041745367 @default.
• W1618705644 hasAuthorship W1618705644A5046772202 @default.
• W1618705644 hasAuthorship W1618705644A5054304877 @default.
• W1618705644 hasAuthorship W1618705644A5057084037 @default.
• W1618705644 hasAuthorship W1618705644A5057593886 @default.
• W1618705644 hasAuthorship W1618705644A5060121000 @default.
• W1618705644 hasAuthorship W1618705644A5069419008 @default.
• W1618705644 hasAuthorship W1618705644A5069887195 @default.
• W1618705644 hasAuthorship W1618705644A5071466957 @default.
• W1618705644 hasAuthorship W1618705644A5078922292 @default.
• W1618705644 hasAuthorship W1618705644A5083693070 @default.
• W1618705644 hasAuthorship W1618705644A5091664535 @default.
• W1618705644 hasBestOaLocation W16187056441 @default.
• W1618705644 hasConcept C126322002 @default.
• W1618705644 hasConcept C156957248 @default.
• W1618705644 hasConcept C2778837598 @default.
• W1618705644 hasConcept C2780007613 @default.
• W1618705644 hasConcept C2780076729 @default.
• W1618705644 hasConcept C2780829020 @default.
• W1618705644 hasConcept C2781057849 @default.
• W1618705644 hasConcept C2781107747 @default.
• W1618705644 hasConcept C44249647 @default.
• W1618705644 hasConcept C71924100 @default.
• W1618705644 hasConcept C90924648 @default.
• W1618705644 hasConceptScore W1618705644C126322002 @default.
• W1618705644 hasConceptScore W1618705644C156957248 @default.
• W1618705644 hasConceptScore W1618705644C2778837598 @default.
• W1618705644 hasConceptScore W1618705644C2780007613 @default.
• W1618705644 hasConceptScore W1618705644C2780076729 @default.
• W1618705644 hasConceptScore W1618705644C2780829020 @default.
• W1618705644 hasConceptScore W1618705644C2781057849 @default.
• W1618705644 hasConceptScore W1618705644C2781107747 @default.
• W1618705644 hasConceptScore W1618705644C44249647 @default.
• W1618705644 hasConceptScore W1618705644C71924100 @default.
• W1618705644 hasConceptScore W1618705644C90924648 @default.

• next